🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to scientists.

An International Challenge

Cases of gonorrhoea are on the rise worldwide, with data suggesting in excess of 82 million instances per year. Particularly high rates are seen in Africa and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This treatment, which is also used to treat UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a significant shift in the therapy of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Results and Global Access

According to findings released by a prominent scientific publication, zoliflodacin successfully treated more than 90% of cases of the STI. This establishes an equal footing with the existing first-line therapy, which uses two antibiotics. The research involved nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in a wide range of developing nations.

Doctors treating patients have expressed hope. The availability of a easy-to-administer therapy like this is described as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to lessen the impact of the infection for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.